Use of High-Dose Influenza and Live Attenuated Influenza Vaccines by US Primary Care Physicians

Abstract

Background

Several different types of influenza vaccine are licensed for use in adults in the USA including high-dose inactivated influenza vaccine (HD-IIV) and live attenuated influenza vaccine (LAIV). HD-IIV is licensed for use in adults ≥ 65 years, and recommendations for use of LAIV have changed several times in recent years.

Objective

We sought to examine family physicians’ (FPs) and general internal medicine physicians’ (GIMs) perceptions, knowledge, and practices for use of HD-IIV and LAIV during the 2016–2017 and 2018–2019 influenza seasons.

Design

E-mail and mail surveys conducted February–March 2017, January–February 2019.

Participants

Nationally representative samples of FPs and GIMs.

Main Measures

Surveys assessed HD-IIV practices (2017), knowledge and perceptions (2019), and LAIV knowledge and practices (2017, 2019).

Key Results

Response rates were 67% (620/930) in 2017 and 69% (642/926) in 2019. Many physicians believed HD-IIV is more effective than standard dose IIV in patients ≥ 65 years (76%) and reported their patients ≥ 65 years believe they need HD-IIV (67%). Most respondents incorrectly thought ACIP preferentially recommends HD-IIV for adults ≥ 65 years (88%); 65% “almost always/always” recommended HD-IIV for adults ≥ 65 years. Some physicians incorrectly thought ACIP preferentially recommends HD-IIV for adults < 65 years with cardiopulmonary disease (38%) or immunosuppression (48%); some respondents recommended HD-IIV for these groups (25% and 28% respectively). In 2017, 88% of respondents knew that ACIP recommended against using LAIV during the 2016–2017 influenza season, and 4% recommended LAIV to patients. In 2019, 63% knew that ACIP recommended that LAIV could be used during the 2018–2019 influenza season, and 8% recommended LAIV.

Conclusions

Many physicians incorrectly thought ACIP had preferential recommendations for HD-IIV. Physicians should be encouraged to use any available age-appropriate influenza vaccine to optimize influenza vaccination particularly among older adults and patients with chronic conditions who are more vulnerable to severe influenza disease.

This is a preview of subscription content, access via your institution.

Figure. 1

Abbreviations

AAFP:

American Academy of Family Physicians

ACIP:

(Advisory Committee on Immunization Practices

ACP:

American College of Physicians

CDC:

Centers for Disease Control and Prevention

FP:

Family physician

FDA:

Food and Drug Administration

GIM:

General internal medicine physician

HD-IIV:

High-dose inactivated influenza vaccine

HMO:

Health maintenance organization

IIV:

Inactivated influenza vaccine

LAIV:

Live attenuated influenza vaccine

US:

United States

References

  1. 1.

    Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season. MMWR Recomm Rep 2018;67(3):1-20.

    Article  Google Scholar 

  2. 2.

    Centers for Disease Control and Prevention. Fluzone High-Dose Seasonal Influenza Vaccine. 2018; https://www.cdc.gov/flu/prevent/qa_fluzone.htm. Accessed Jun 18, 2019, 2019.

  3. 3.

    Lee JKH, Lam GKL, Shin T, et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccin 2018;17(5):435-443.

    CAS  Article  Google Scholar 

  4. 4.

    Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis 2015;15(3):293-300.

    Article  Google Scholar 

  5. 5.

    Richardson DM, Medvedeva EL, Roberts CB, Linkin DR, Centers for Disease C, Prevention Epicenter P. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans. Clin Infect Dis 2015;61(2):171-176.

    Article  Google Scholar 

  6. 6.

    Young-Xu Y, Van Aalst R, Mahmud SM, et al. Relative Vaccine Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among Veterans Health Administration Patients. J Infect Dis 2018; 217(11):1718-1727.

    Article  Google Scholar 

  7. 7.

    Gravenstein S, Davidson HE, Taljaard M, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir Med 2017; 5(9):738-746.

    Article  Google Scholar 

  8. 8.

    DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014; 371(7):635-645.

    Article  Google Scholar 

  9. 9.

    Robertson CA, DiazGranados CA, Decker MD, Chit A, Mercer M, Greenberg DP. Fluzone(R) High-Dose Influenza Vaccine. Expert Rev Vaccin 2016; 15(12):1495-1505.

    CAS  Article  Google Scholar 

  10. 10.

    Van Ermen A, Hermanson MP, Moran JM, Sweitzer NK, Johnson MR, Vardeny O. Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study. Eur J Heart Fail 2013; 15(5):560-564.

    Article  Google Scholar 

  11. 11.

    Natori Y, Shiotsuka M, Slomovic J, et al. A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients. Clin Infect Dis 2018; 66(11):1698-1704.

    CAS  Article  Google Scholar 

  12. 12.

    Jamshed S, Walsh EE, Dimitroff LJ, Santelli JS, Falsey AR. Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial. Vaccine. 2016; 34(5):630-635.

    CAS  Article  Google Scholar 

  13. 13.

    McKittrick N, Frank I, Jacobson JM, et al. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med 2013; 158(1):19-26.

    Article  Google Scholar 

  14. 14.

    DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty. Vaccine. 2015; 33(36):4565-4571.

    CAS  Article  Google Scholar 

  15. 15.

    Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines. MMWR Recomm Rep 2016; 65(5):1-54.

    Article  Google Scholar 

  16. 16.

    U.S. Food & Drug Administration. FDA Information Regarding FluMist Quadrivalent Vaccine. 2018; https://www.fda.gov/vaccines-blood-biologics/vaccines/fda-information-regarding-flumist-quadrivalent-vaccine. Accessed Jun 18, 2019, 2019.

  17. 17.

    Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep 2014; 63(32):691-697.

    PubMed  PubMed Central  Google Scholar 

  18. 18.

    Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356(7):685-696.

    CAS  Article  Google Scholar 

  19. 19.

    Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25(10):860-869.

    Article  Google Scholar 

  20. 20.

    Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25(10):870-879.

    Article  Google Scholar 

  21. 21.

    Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season. Am J Transplant 2015; 15(10):2767-2775.

    Article  Google Scholar 

  22. 22.

    Davlin SL, Blanton L, Kniss K, et al. Influenza Activity - United States, 2015-16 Season and Composition of the 2016-17 Influenza Vaccine. MMWR Morb Mortal Wkly Rep 2016; 65(22):567-575.

    Article  Google Scholar 

  23. 23.

    Crane LA, Daley MF, Barrow J, et al. Sentinel physician networks as a technique for rapid immunization policy surveys. Eval Health Prof 2008; 31(1):43-64.

    Article  Google Scholar 

  24. 24.

    Brtnikova M, Crane LA, Allison MA, Hurley LP, Beaty BL, Kempe A. A method for achieving high response rates in national surveys of U.S. primary care physicians. PLoS One. 2018; 13(8):e0202755.

    Article  Google Scholar 

  25. 25.

    Dillman DA, Smyth JD, Christian LM. Internet, phone, mail, and mixed-mode surveys: the tailored design method. Wiley; 2014.

  26. 26.

    Atkeson LR, Adams AN, Bryant LA, Zilberman L, Saunders KL. Considering mixed mode surveys for questions in political behavior: using the Internet and mail to get quality data at reasonable costs. Polit Behav 2011; 33(1):161-178.

    Article  Google Scholar 

  27. 27.

    McMahon SR, Iwamoto M, Massoudi MS, et al. Comparison of e-mail, fax, and postal surveys of pediatricians. Pediatrics. 2003; 111(4):e299-e303.

    Article  Google Scholar 

  28. 28.

    McGrath LJ, Brookhart MA. On-label and off-label use of high-dose influenza vaccine in the United States, 2010-2012. Hum Vaccin Immunother 2015; 11(3):537-544.

    Article  Google Scholar 

  29. 29.

    Chit A, Roiz J, Briquet B, Greenberg DP. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors. Vaccine. 2015; 33(5):734-741.

    Article  Google Scholar 

  30. 30.

    Raviotta JM, Smith KJ, DePasse J, et al. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults. J Am Geriatr Soc 2016; 64(10):2126-2131.

    Article  Google Scholar 

  31. 31.

    Shireman TI, Ogarek J, Gozalo P, et al. Cost Benefit of High-Dose vs Standard-Dose Influenza Vaccine in a Long-Term Care Population During an A/H1N1-Predominant Influenza Season. J Am Med Dir Assoc 2019.

  32. 32.

    DiazGranados CA, Saway W, Gouaux J, et al. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age. Vaccine. 2015; 33(51):7188-7193.

    CAS  Article  Google Scholar 

  33. 33.

    Halasa NB, Savani BN, Asokan I, et al. Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Hematopoietic Stem Cell Transplantation Patients. Biol Blood Marrow Transplant 2016; 22(3):528-535.

    CAS  Article  Google Scholar 

  34. 34.

    Bosaeed M, Kumar D. Seasonal influenza vaccine in immunocompromised persons. Hum Vaccin Immunother 2018; 14(6):1311-1322.

    Article  Google Scholar 

  35. 35.

    Pereira JA, Gilca V, Waite N, Andrew MK. Canadian older adults' perceptions of effectiveness and value of regular and high-dose influenza vaccines. Hum Vaccin Immunother 2019; 15(2):487-495.

    Article  Google Scholar 

  36. 36.

    Nowak GJ, Sheedy K, Bursey K, Smith TM, Basket M. Promoting influenza vaccination: insights from a qualitative meta-analysis of 14 years of influenza-related communications research by U.S. Centers for Disease Control and Prevention (CDC). Vaccine. 2015; 33(24):2741-2756.

    Article  Google Scholar 

  37. 37.

    Almasi EA, Stafford RS, Kravitz RL, Mansfield PR. What are the public health effects of direct-to-consumer drug advertising? PLoS Med 2006; 3(3):e145.

    Article  Google Scholar 

  38. 38.

    Frosch DL, Grande D, Tarn DM, Kravitz RL. A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising. Am J Public Health 2010; 100(1):24-32.

    Article  Google Scholar 

  39. 39.

    Faerber AE, Kreling DH. Content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs. J Gen Intern Med 2014; 29(1):110-118.

    Article  Google Scholar 

  40. 40.

    Klara K, Kim J, Ross JS. Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines. J Gen Intern Med 2018; 33(5):651-658.

    Article  Google Scholar 

  41. 41.

    Ventola CL. Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic? P T 2011; 36(10):669-684.

    PubMed  PubMed Central  Google Scholar 

  42. 42.

    Centers for Disease Control and Prevention. Early-Season Flu Vaccination Coverage–United States, November 2018. 2018; https://www.cdc.gov/flu/fluvaxview/nifs-estimates-nov2018.htm. Accessed Aug 14, 2020, 2020.

Download references

Acknowledgments

The authors would like to thank Bellinda Schoof, MHA, at the AAFP, Arlene Weissman, PhD, and Linda Harris from the ACP, and the leaders of the AAFP and ACP for collaborating in the establishment of the sentinel networks in family medicine and general internal medicine. The authors would like to thank Erin Burns, Alicia Fry, and Mark Thompson from the Centers for Disease Control and Prevention for assistance developing the survey questions. We would also like to thank all general internists and family medicine physicians in the networks for participating and responding to this survey.

Funding

This publication was supported by Cooperative Agreement Number 1 U01 IP000849-03, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jessica R. Cataldi MD, MSCS.

Ethics declarations

Conflict of Interest

None of the authors has any conflicts of interest.

Financial Disclosures

None of the authors has any financial disclosures.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(DOCX 23 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cataldi, J.R., Hurley, L.P., Lindley, M.C. et al. Use of High-Dose Influenza and Live Attenuated Influenza Vaccines by US Primary Care Physicians. J GEN INTERN MED (2021). https://doi.org/10.1007/s11606-020-06397-7

Download citation

KEY WORDS

  • influenza vaccine
  • immunization
  • vaccination
  • influenza